AMPD3 Gene AMP Deaminase Deficiency (Erythrocytic) Genetic Test

Executive Summary & Core Metrics

Clinical Assurance & Your Pathway to Precision

99.9% Diagnostic Sensitivity – ISO 9001:2015 accredited processing eliminates analytical uncertainty.
VIP Mobile Phlebotomy – Hospital-grade home collection (8 AM – 11 PM) with full cold-chain integrity.
Post-Test Clinical Guidance – Complimentary telehealth interpretation session with a metabolic specialist.
Direct Insurance Billing – Submit your policy via WhatsApp at +971 54 548 8731 for instant verification.

Test Overview & Methodology

This Next-Generation Sequencing (NGS) test examines the AMPD3 gene for pathogenic variants linked to erythrocytic adenosine monophosphate deaminase deficiency—a rare inborn error of purine metabolism. Designed for symptomatic patients, at-risk families, and health-optimisation seekers, the analysis provides definitive molecular confirmation with full clinical actionability, far surpassing traditional enzyme assays.

Parameter	Our NGS Test (ISO Accredited)	Closest Alternative (Enzyme Assay)
Diagnostic Precision	>99.9% analytical sensitivity & specificity; detects SNVs, indels, CNVs	~85% sensitivity; may miss carriers or regulatory mutations
Methodology	Targeted NGS with 100% coverage of coding exons ±10 bp splice sites + MLPA confirmation	Biochemical AMP deaminase activity assay (prone to pre-analytical variability)
Turnaround Time	3 to 4 Weeks (enabling timely family planning & metabolic management)	2–6 weeks, often requiring fresh red blood cells

Physician Insight & Safety Protocols

“As a consultant medical geneticist, I emphasize that this test provides a definitive molecular diagnosis, but it must be interpreted within the full clinical context. Always discuss results with your genetic counselor or specialist before making any health decisions.”

— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Advisory: Pre-Test Medication and Supplement Safety

Do not discontinue, modify, or skip any prescribed medication or supplement in preparation for this test. Always consult your treating physician first.

Safety Exclusion Criteria & Emergency Red Flags

This test is not indicated for acute crisis diagnosis; in case of severe hemolytic anemia, chest pain, or sudden muscle weakness, seek emergency care immediately.
The test requires stable clinical condition; active severe infection or recent blood transfusion (<2 weeks) may interfere with DNA quality.
For minors, UAE Federal Decree-Law No. 4 of 2016 on Medical Liability mandates parental consent and genetic counselling.
If you experience unexplained bruising, jaundice, or dark urine while awaiting results, contact your doctor or emergency services without delay.

Patient FAQ & Clinical Guidance

1. What is the AMPD3 genetic test and what does it diagnose?

Snippet: The AMPD3 NGS test sequences the adenosine monophosphate deaminase 3 gene to identify mutations causing erythrocytic enzyme deficiency. It confirms hereditary AMP deaminase deficiency linked to metabolic crises, exercise intolerance, or asymptomatic carrier status. Early diagnosis enables personalised dietary and lifestyle adjustments to prevent complications.

2. Why is genetic counseling required before this test?

Snippet: Genetic counselling ensures informed consent, pedigree analysis, and understanding of inheritance patterns before testing. Our service includes a pre-virtual session to map family history, assess recurrence risks, and explain potential outcomes, fully adhering to UAE PDPL confidentiality standards.

3. How long do results take and how will I receive them?

Snippet: Results are delivered within 3 to 4 weeks via secure online portal with clinical guidance. You will receive a comprehensive PDF report including variant interpretation, clinical significance, and actionable recommendations, followed by a complimentary telehealth consultation with a DHA-licensed metabolic specialist.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance: This service strictly adheres to UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and safety are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. All data is processed exclusively within sovereign UAE servers.

Quality Accreditation: ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) – Guaranteeing laboratory quality management and patient safety.

Facility Licensing: DNA Labs UAE | DHA License No. 1143 – authorised for mobile phlebotomy and all testing procedures across Dubai Healthcare City and the UAE.

Clinical & Logistical Metadata

Test Name	AMPD3 Gene AMP Deaminase Deficiency (Erythrocytic) Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 Weeks
Sample Type / Matrix	Peripheral whole blood (EDTA) – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection
Methodology Used	Targeted NGS with 100% coverage of coding exons ±10 bp splice sites + MLPA confirmation
ICD-10-CM Code	D55.2
LOINC Code	96778-1
DHA Facility License & Laboratory Address	DNA Labs UAE \| DHA License 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE